Much like the American Dream, entrepreneurship is a national ideal of the United States representing a belief that prosperity and success can be achieved through hard, tireless work. Developing a technological innovation that will change the world for the better is what it's all about these days, especially for young people trying to make a name for themselves on college campuses. Students arrive on school grounds driven by two thoughts – fear of failure and desire for success – both of which naturally lead down the road to entrepreneurship.

Boards aren’t working. It’s been more than a decade since the first wave of post-Enron regulatory reforms and, despite a host of guidelines from independent watchdogs such as the International Corporate Governance Network, most boards aren’t delivering on their core mission: providing strong oversight and strategic support for management’s efforts to create long-term value.

The Swiss firm, which this week filed a melanoma combination drug for US approval, spent $10bn on research into new products, ahead of rivals such as Novartis, which spent $9.8bn and the $8.2bn spent by Johnson & Johnson (J&J).

Shareholders in British drugmaker GlaxoSmithKline (GSK.L) have approved a planned deal with Switzerland's Novartis (NOVN.VX), which will see the two pharmaceutical groups trade more than $20 billion (12.7 billion pounds) of assets.

A coalition of geneticists and computer programmers calling itself the Global Alliance for Genomics and Health is developing protocols for exchanging DNA information across the Internet. The researchers hope their work could be as important to medical science as HTTP, the protocol created by Tim Berners-Lee in 1989, was to the Web.

United Therapeutics (Nasdaq: UTHR) announced two senior executive promotions as well as changes to Martine Rothblatt, Ph.D's compensation program.

University of Massachusetts President Robert Caret will take over as University System of Maryland's fourth chancellor in July.

Let’s be clear: Martine Rothblatt is just plain more of a lawyer than anybody else in this town.

The 60-year-old grandmother and CEO of United Therapeutics, the Silver Spring-based biotech she founded to help save her younger daughter’s life, banked $38 million last year. It made her the nation’s highest-paid female executive. It also made her the nation’s highest-paid transgendered person, as she had sex reassignment surgery in 1994.

The FDA offered up an early retrospective of the 2014 year of approvals Friday with a rundown the regulator feels pretty good about. “Our Center for Drug Evaluation and Research (CDER) has so far approved 35 novel drugs in 2014 compared to 27 in 2013,” FDA commissioner Margaret Hamburg wrote on the agency's FDA Voice blog.

The world of technology is growing at a rapid pace, nothing new, but next year could involve some major cashing in for some health tech industries. With the help of some leading analyst firms, Business Insider put together a list of the trends that are predicted to be really booming next year.

Healthcare workers treating Ebola victims are at a great danger of contracting the disease, as recent events in western Africa have shown. Currently available protective suits tend to require complicated procedures when putting on and taking off, are difficult to breathe in, and obscure the clinician’s face. A team at Johns Hopkins has developed, and just won a grant from the U.S. Agency for International Development (USAID) to further perfect, a new protective suit for use when treating highly infectious patients.

Ebola dominated the news in the second half of the year. Other important news was the debate on maintenance of certification, the first baby born after uterine transplant, and the change in HHS leadership.

Cathal Garvey used to work in cancer research. Now he is the scientific director of IndieBio, a biotech accelerator based in Cork, Ireland which is about to open a branch in San Francisco. Garvey originally studied genetics. "I got into genetics after seeing a documentary about it when it was quite young." he says."I had already decided that I was going to be a biologist at an even younger age. And then I thought ‘Oh my God, living things operate on a code.’"

Maryland is not waiting for the new year or a new governor to start taking applications for a program intended to boost business development around colleges and universities.

The state is now taking applications for its new Regional Institution Strategic Enterprise Zone program(called the "Rise Zone" program for short). It requires two application stages.

Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application to conduct a Phase 1/2 clinical study of ADXS-HPV (ADXS11-001) alone or in combination with MedImmune's investigational anti-PD-L1 immune checkpoint inhibitor, MEDI4736, for the treatment of advanced, recurrent or refractory human papillomavirus (HPV)-associated cervical cancer and HPV-associated head and neck cancer. The trial is expected to begin patient enrollment in early 2015. 

With new articles published in journals every week and scores of labs constantly at work, scientists at this university stay productive.

And a new ranking has found that university researchers live up to that standard — when it comes to science research, this university is one of the most prolific in the world.

NHLBI is soliciting applications from small businesses to develop and validate novel in vitro human cell-based tools for predicting the responses of individual patients to cystic fibrosis transmembrane conductance regulator (CFTR)-directed therapeutics for cystic fibrosis (CF) lung disease. Proposed research projects are expected to focus on the development of highly innovative cell-based systems that recapitulate a patient-specific CFTR phenotype to create a personalized study platform to examine response to CFTR-directed therapeutics. The models developed must be based on live cells from humans harboring CFTR mutations associated with CF. While the primary goal of this initiative is to promote precision medicine and optimization of treatment at the personal level, it may also yield as a secondary benefit the ability to select appropriate treatments for CF at an earlier age.

Stem cell-derived blood and platelet products have the potential to meet critical medical needs. Remaining challenges exist in both the manufacturing process and additional discovery research. The manufacturing process needs to be made more efficient and cost-effective while assuring the effectiveness and safety of the blood products and enable their commercial viability. RFA-HL-15-022 supports R01 grants to address the basic or early translational research needs whereas RFA-HL-15-029 and RFA-HL-15-030 support small business awards to enable further advances in the manufacturing processes (tools and technologies) to take advantage of the existing knowledge and recent advances in the field to produce safe and functional blood and platelet products at reduced costs.

Chairwoman of the Senate Appropriations Committee and the Commerce, Justice, Science (CJS) Appropriations Subcommittee, today announced the Consolidated and Further Continuing Appropriations Act of 2015 provides increased funding to support American jobs and innovation, including funds for trade and economic development programs, and investment in scientific research and exploration.

A rich new Credit Suisse report, “Global Biotechnology – An Outlook for 2015,” was flush with cool data about trends in the biotech industry. The analysis lists out 10 key themes for 2015. Here’s the highlight reel:

Building a biotechnology startup is a lot like getting a private university education: To make progress, you have to get past the high-cost barrier to entry.

First and foremost, biotech requires expensive clinical studies and the use of state-of-the-art manufacturing facilities.

The U.S. Senate gave final passage on Saturday to an overdue spending bill for the 2015 fiscal year that provides modest increases for research, while holding education spending mostly flat.

As reported in a story earlier this morning, Oregon is preparing to join 15 states that have implemented rules to let businesses raise money through investment crowdfunding.

On October 9, 2014, the Investment Advisory Committee of the SEC issued its much awaited recommendations on the "Accredited Investor" definition of Regulation D of the '33 Act. This is in response to the SEC's Request for Comments on the definition of "Accredited Investor" in its release relating to Proposed Rules for Regulation D and Form D, which mainly related to general solicitation (for the full text of that release, see here).

An advanced protective suit for healthcare workers who treat Ebola patients, devised by a Johns Hopkins team, has been selected as a winning design in a global competition aimed at quickly getting new tools into the field to combat this deadly disease.

ATCC, the premier global biological materials resource and standards organization, and LGC, a leading global producer and distributor of reference materials and proficiency testing (PT) programs, announce a new agreement to provide high-quality proficiency testing programs supporting the food, beverage, animal feed, and pharmaceutical quality control markets in the United States.

San Diego-based BioMed Realty Trust Inc. has sold a 289,900-square-foot bio-manufacturing facility at 9911 Belward Campus Drive for $322.5 million to private equity firm GI Partners.

The selling price translates into a whopping $1,112 per square foot.

Johns Hopkins University’s Applied Physics Laboratory says it has experienced record growth for initiatives to move its scientific discoveries into the commercial sector in 2014.

Healthcare giant McKesson Corp. plans an aggressive move into venture capital funding for healthcare technology, expecting to commit several hundred million dollars to the effort over the next five to eight years, and hiring long-time venture capitalist Tom Rodgers as managing director of strategic venture capital operations.

University System of Maryland Chancellor William E. Kirwan, who announced in the spring his plans to step down, said this week that he will likely remain in his post at least through February as the search continues for his successor.

As an offshoot of PatentStat, I’ve assembled a set of graphs of patent inventor locations, focusing in 33 industry sectors.

Bedsores, diabetic ulcers and other chronic wounds cost the U.S. health care system $30 billion a year. Why? At least in part because the primary tool doctors and nurses use to track wounds is a basic ruler.

A ruler can measure the size of a wound, but does little to track other important qualities, such as changes in shape and tissue color. Consider that patients are usually cared for by a rotating team of nurses, who may each interpret a wound's appearance differently, and it's easier to see how so much money is spent tending to preventable (or at least treatable) conditions.

Recent efforts between the University of Maryland (UMD) and Bethesda-based Weinberg Medical Physics LLC (WMP) have led to a new technique to magnetically deliver drug-carrying particles to hard-to-reach targets. The method has the potential to transform the way deep-tissue tumors and other diseases are treated.

Pieris AG announced today the initiation of a Phase I clinical trial with PRS-080, an anti-hepcidin Anticalin® therapeutic protein designed to treat anemia. The trial is a placebo-controlled, single ascending dose evaluation of the compound's safety and tolerability in healthy volunteers. Conducted in Germany, the trial is underway and patients from the first cohort have been dosed.